21 Jun 2010
Dublin, Ireland – June 21, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it was notified on June 21, 2010 by Ms Anne Minto, a Non-Executive Director of the Company, of an acquisition on the same day of 2,228 ordinary shares of £0.05 each (“Shares”). The Shares were acquired at a price of £14.53645 per Share.
Following this transaction, Ms Minto holds 2,228 Shares in the Company.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Deputy Company Secretary
For further information please contact:
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
Eric Rojas (North America)
+1 781 482 0999
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.